NCT02054052View on ClinicalTrials.gov

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Non-small Cell Lung CancerMalignant Pleural Effusion
Interventions
DRUG

Bevacizumab

Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE

Trial Locations (1)

510120

The First Affliliated Hospital of Guangzhou MC, Guangzhou

All Listed Sponsors
lead

Haihong Yang, MD, Pricipal investigator

OTHER

NCT02054052 - Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer | Biotech Hunter | Biotech Hunter